Twenty-two New Patents Are Added To ViaCyte’s Intellectual Property Portfolio
President and CEO, Paul Laikind, PhD to present at 2017 Biotech Showcase SAN DIEGO, January 4, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced the addition of twenty-two new patents in 2016. In early 2016 the Company announced the consolidation of the assets of the Janssen BetaLogics group into ViaCyte. Five of